Abstract
The introduction of long-acting beta agonists (LABAs) was considered a major advance in bronchodilator therapy with evidence that their use led to improved lung function and quality of life. However, the use of LABAs has raised safety concerns, such as their potential to provoke severe asthma exacerbations (SAEs) and death. This systematic review of major findings discusses the safety controversy surrounding LABA therapy and provides background for the U.S. Food and Drug Administrations warnings concerning LABA use. Findings from large clinical trials and several meta-analyses are described and compared in terms of their implications for the safety of LABAs. Monotherapy LABA therapy in the treatment of asthma remains controversial and is not recommended by the most recent asthma management guidelines. Despite the existence of numerous published studies, we conclude that more well-designed research on this topic --- to determine whether LABAs are associated with SAEs, such as asthma-related hospitalizations, intubations, and emergency room visits, or death --- is required. Particularly needed is research that makes use of large, secondary longitudinal databases.
Keywords: Long-acting beta agonists (LABAs), asthma, SMART trial, safety controversy, African Americans, pediatric LABA use
Current Drug Safety
Title: Evaluating Safety of Long-Acting Beta Agonists (LABAs) in Patients with Asthma
Volume: 5 Issue: 3
Author(s): Boyang Bian, Christina M.L. Kelton, Patricia R. Wigle and Jeff J. Guo
Affiliation:
Keywords: Long-acting beta agonists (LABAs), asthma, SMART trial, safety controversy, African Americans, pediatric LABA use
Abstract: The introduction of long-acting beta agonists (LABAs) was considered a major advance in bronchodilator therapy with evidence that their use led to improved lung function and quality of life. However, the use of LABAs has raised safety concerns, such as their potential to provoke severe asthma exacerbations (SAEs) and death. This systematic review of major findings discusses the safety controversy surrounding LABA therapy and provides background for the U.S. Food and Drug Administrations warnings concerning LABA use. Findings from large clinical trials and several meta-analyses are described and compared in terms of their implications for the safety of LABAs. Monotherapy LABA therapy in the treatment of asthma remains controversial and is not recommended by the most recent asthma management guidelines. Despite the existence of numerous published studies, we conclude that more well-designed research on this topic --- to determine whether LABAs are associated with SAEs, such as asthma-related hospitalizations, intubations, and emergency room visits, or death --- is required. Particularly needed is research that makes use of large, secondary longitudinal databases.
Export Options
About this article
Cite this article as:
Bian Boyang, M.L. Kelton Christina, R. Wigle Patricia and J. Guo Jeff, Evaluating Safety of Long-Acting Beta Agonists (LABAs) in Patients with Asthma, Current Drug Safety 2010; 5 (3) . https://dx.doi.org/10.2174/157488610791698316
DOI https://dx.doi.org/10.2174/157488610791698316 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Drugs of Abuse and their Detection Methodologies: Contribution of Chemical Sensor
Current Organic Chemistry What we have Learned from Animal Models of Mycoplasma pneumoniae Disease: Virulence Mechanisms and Host Responses
Current Pediatric Reviews Anti-IgE Monoclonal Antibody (Omalizumab) in the Treatment of Atopic Asthma and Allergic Respiratory Diseases
Current Drug Targets - Inflammation & Allergy HIF-1α Deficiency Perturbs T and B Cell Functions
Current Pharmaceutical Design Anti-TNF Treatment in Rheumatoid Arthritis
Current Pharmaceutical Design 3,4-Dihydropyrimidin-2(1H)-one C5 Amides as Inhibitors of T NFα Production: Synthesis, Biological Evaluation and Molecular Modeling
Letters in Drug Design & Discovery Recent Developments in Medicated Lozenges: A Promising Dosage Form for the Effective Delivery of Therapeutic Agents
Drug Delivery Letters Beta-Blockers: Effects on Bone Mineral Density and Fracture Risk
Current Rheumatology Reviews Combinatorial Application of Multiple High-throughput Biotechnologies for the Study of Autoimmune Diseases
Current Pharmaceutical Analysis Inflammatory Responses to Respiratory Syncytial Virus (RSV) Infection and the Development of Immunomodulatory Pharmacotherapeutics
Current Medicinal Chemistry Automated Electrophysiology in Drug Discovery
Current Pharmaceutical Design A Conceptual Framework of Comorbidity for Investigation in the Context of Psychiatric Disturbance
Current Psychiatry Reviews Effects of Amine Oxidases in Allergic and Histamine-Mediated Conditions
Recent Patents on Inflammation & Allergy Drug Discovery An Aggressive Medical Approach for Inflammatory Bowel Disease: Clinical Challenges and Therapeutic Profiles in a Retrospective Hospitalbased Series
Current Clinical Pharmacology Pharmacogenetics, Pharmacogenomics and Epigenetics of Nrf2-regulated Xenobioticmetabolizing Enzymes and Transporters by Dietary Phytochemical and Cancer Chemoprevention
Current Drug Metabolism Intestinal Barrier Dysfunction Participates in the Pathophysiology of Ischemic Stroke
CNS & Neurological Disorders - Drug Targets Rational Design and Development of Colon-Specific Prodrugs
Current Topics in Medicinal Chemistry Thymoquinone Shows the Diverse Therapeutic Actions by Modulating Multiple Cell Signaling Pathways: Single Drug for Multiple Targets
Current Pharmaceutical Biotechnology Circulating Advanced Oxidation Protein Products as Oxidative Stress Biomarkers and Progression Mediators in Pathological Conditions Related to Inflammation and Immune Dysregulation
Current Medicinal Chemistry Heteromerization of G Protein-Coupled Receptors: Relevance to Neurological Disorders and Neurotherapeutics
CNS & Neurological Disorders - Drug Targets